Home » EMEA: Contrast Agents Associated With Kidney Risk
EMEA: Contrast Agents Associated With Kidney Risk
December 17, 2009
Manufacturers of contrast agents containing gadolinium that are used for magnetic resonance scans are being asked to revise the drug labeling to warn of
the risk of developing nephrogenic systemic fibrosis (NSF), the European Medicines Agency (EMEA) says.
To View This Article:
Subscribe To International Pharmaceutical Regulatory Monitor